140 results
8-K
EX-10.1
u8s lc5quok3dnm
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
S-8
EX-5.1
r3a6px1 0x5
30 Nov 23
Registration of securities for employees
4:16pm
S-8
5ja95 cqdz6kmz6x
30 Nov 23
Registration of securities for employees
4:16pm
S-8
briireegq2 3re
30 Nov 23
Registration of securities for employees
4:16pm
8-K/A
EX-99.3
0c996rwn owqr0ib
10 Aug 23
Financial Statements and Exhibits
4:05pm
8-K
EX-10.2
zgqlrlb pzogd
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.1
bi3x6b0yozfs6ell0h5
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.3
0oacnutpy
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
sqe6wk 2zw
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
ogfo1wnwnoc22 n5nb3
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
424B3
wvz7zkkqri5f
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
2tq80k9rv7 3kkjt
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4/A
EX-99.3
mcmy3674vaxz1d0d38
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4/A
EX-5.1
fx037u76q0o739ou
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm